-
Je něco špatně v tomto záznamu ?
Bleeding phenotype according to factor level in 825 children with nonsevere hemophilia: data from the PedNet cohort
MS. de Kovel, C. Escuriola-Ettingshausen, C. Königs, S. Ranta, K. Fischer, PedNet Study Group
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
NLK
Free Medical Journals
od 2003 do Před 1 rokem
ROAD: Directory of Open Access Scholarly Resources
od 2003
- MeSH
- dítě MeSH
- faktor IX * genetika MeSH
- faktor VIII * MeSH
- fenotyp * MeSH
- hemofilie A * krev diagnóza komplikace MeSH
- hemofilie B krev diagnóza genetika MeSH
- Kaplanův-Meierův odhad MeSH
- kohortové studie MeSH
- kojenec MeSH
- krvácení * krev MeSH
- lidé MeSH
- mladiství MeSH
- předškolní dítě MeSH
- stupeň závažnosti nemoci MeSH
- věk při počátku nemoci MeSH
- Check Tag
- dítě MeSH
- kojenec MeSH
- lidé MeSH
- mladiství MeSH
- mužské pohlaví MeSH
- předškolní dítě MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: Information on bleeding phenotype in nonsevere hemophilia may be used to determine target factor levels for prophylaxis or gene therapy in severe hemophilia. OBJECTIVES: To assess the association between endogenous factor level and bleeding phenotype in children with nonsevere (factor [F]VIII/FIX activity 1%-25%) hemophilia A (HA) and B without prophylaxis. METHODS: Data on annualized bleeding rate (ABR), annualized joint bleeding rate (AJBR), and onset of bleeding were extracted from the international PedNet cohort including children born since 2000. Mean ABR and AJBR were modeled and compared according to FVIII/FIX endogenous activity (1%-2%, 3%-5%, 6%-10%, 11%-15%, 16%-20%, and 21%-25%) using negative binomial regression. Onset of bleeding was analyzed using Kaplan-Meier survival curves. RESULTS: Eight hundred twenty-five children (40% with moderate hemophilia; 87% with HA) with median follow-up of 7.4 years/child were included. The median age at onset of bleeding and median bleeding rates changed with increasing endogenous activity. From endogenous FVIII 1% to 2% to 21% to 25%, the age at onset of bleeding changed from a median of 1.4 to 14.2 years, ABR from 1.6 to 0.1/y, and AJBR from 0.5 to 0.0/y. From endogenous FIX 1% to 2% to 16% to 25%, the onset of bleeding changed from a median of 1.7 to 6.1 years, ABR from 0.5 to 0.1/y, and AJBR from 0.1 to 0.0/y. The negative correlation between AJBR and factor level was most strongly pronounced up to a factor level of 6% in HA and hemophilia B. CONCLUSION: Endogenous factor activity of >5% was identified as a threshold to significantly lower joint bleeding rate, while FVIII levels >15% and FIX levels >10% were sufficient to achieve the goal of 0 bleeds in this pediatric cohort.
Hämophilie Zentrum Rhein Main GmbH Frankfurt Germany
PedNet Haemophilia Research Foundation Baarn The Netherlands
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24019152
- 003
- CZ-PrNML
- 005
- 20241024111730.0
- 007
- ta
- 008
- 241015s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jtha.2024.05.030 $2 doi
- 035 __
- $a (PubMed)38866249
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a de Kovel, Marloes S $u PedNet Haemophilia Research Foundation, Baarn, The Netherlands. Electronic address: m.s.dekovel@pednet.eu
- 245 10
- $a Bleeding phenotype according to factor level in 825 children with nonsevere hemophilia: data from the PedNet cohort / $c MS. de Kovel, C. Escuriola-Ettingshausen, C. Königs, S. Ranta, K. Fischer, PedNet Study Group
- 520 9_
- $a BACKGROUND: Information on bleeding phenotype in nonsevere hemophilia may be used to determine target factor levels for prophylaxis or gene therapy in severe hemophilia. OBJECTIVES: To assess the association between endogenous factor level and bleeding phenotype in children with nonsevere (factor [F]VIII/FIX activity 1%-25%) hemophilia A (HA) and B without prophylaxis. METHODS: Data on annualized bleeding rate (ABR), annualized joint bleeding rate (AJBR), and onset of bleeding were extracted from the international PedNet cohort including children born since 2000. Mean ABR and AJBR were modeled and compared according to FVIII/FIX endogenous activity (1%-2%, 3%-5%, 6%-10%, 11%-15%, 16%-20%, and 21%-25%) using negative binomial regression. Onset of bleeding was analyzed using Kaplan-Meier survival curves. RESULTS: Eight hundred twenty-five children (40% with moderate hemophilia; 87% with HA) with median follow-up of 7.4 years/child were included. The median age at onset of bleeding and median bleeding rates changed with increasing endogenous activity. From endogenous FVIII 1% to 2% to 21% to 25%, the age at onset of bleeding changed from a median of 1.4 to 14.2 years, ABR from 1.6 to 0.1/y, and AJBR from 0.5 to 0.0/y. From endogenous FIX 1% to 2% to 16% to 25%, the onset of bleeding changed from a median of 1.7 to 6.1 years, ABR from 0.5 to 0.1/y, and AJBR from 0.1 to 0.0/y. The negative correlation between AJBR and factor level was most strongly pronounced up to a factor level of 6% in HA and hemophilia B. CONCLUSION: Endogenous factor activity of >5% was identified as a threshold to significantly lower joint bleeding rate, while FVIII levels >15% and FIX levels >10% were sufficient to achieve the goal of 0 bleeds in this pediatric cohort.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a hemofilie A $x krev $x diagnóza $x komplikace $7 D006467
- 650 _2
- $a dítě $7 D002648
- 650 12
- $a faktor VIII $7 D005169
- 650 12
- $a fenotyp $7 D010641
- 650 _2
- $a předškolní dítě $7 D002675
- 650 12
- $a krvácení $x krev $7 D006470
- 650 12
- $a faktor IX $x genetika $7 D005164
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a kojenec $7 D007223
- 650 _2
- $a hemofilie B $x krev $x diagnóza $x genetika $7 D002836
- 650 _2
- $a věk při počátku nemoci $7 D017668
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a Kaplanův-Meierův odhad $7 D053208
- 650 _2
- $a kohortové studie $7 D015331
- 650 _2
- $a stupeň závažnosti nemoci $7 D012720
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Escuriola-Ettingshausen, Carmen $u Hämophilie-Zentrum Rhein Main GmbH, Frankfurt, Germany
- 700 1_
- $a Königs, Christoph $u Goethe University Frankfurt, University Hospital, Department of Paediatrics and Adolescent Medicine, Clinical and Molecular Hemostasis, Frankfurt, Germany
- 700 1_
- $a Ranta, Susanna $u Pediatric Coagulation Unit, Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden
- 700 1_
- $a Fischer, Kathelijn $u Center for Benign Haematology, Thrombosis and Haemostasis Van Creveldkliniek, University Medical Center Utrecht, Utrecht, The Netherlands
- 710 2_
- $a PedNet Study Group
- 773 0_
- $w MED00007070 $t Journal of thrombosis and haemostasis : JTH $x 1538-7836 $g Roč. 22, č. 9 (2024), s. 2460-2469
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38866249 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20241015 $b ABA008
- 991 __
- $a 20241024111724 $b ABA008
- 999 __
- $a ok $b bmc $g 2201779 $s 1231125
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 22 $c 9 $d 2460-2469 $e 20240610 $i 1538-7836 $m Journal of thrombosis and haemostasis : JTH $n J Thromb Haemost $x MED00007070
- LZP __
- $a Pubmed-20241015
